Sofinnova Partners has just wrapped up another major milestone, quietly but confidently announcing the close of its newest flagship venture fund, Sofinnova Capital XI.
The Europe-rooted firm—splitting its presence between Paris, London, and Milan—pulled in an impressive €650 million for the vehicle.
Investors From Every Corner of the Globe
The fund’s backers form a wide-ranging mix of well-established institutional names.
Support flowed in from sovereign wealth groups, pharma giants, corporates, insurance firms, foundations, and an array of family offices.
What’s more, the commitments came from every major region—Europe, North America, Asia, and the Middle East.
Most of the firm’s long-time partners returned, but a noticeable wave of new investors also stepped in.
A Mission Focused on Medicine’s Biggest Gaps
The goal for Sofinnova Capital XI is clear: fuel the next crop of biopharma and medical technology innovators trying to solve serious unmet clinical problems.
The team steering this effort includes Partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi—each playing a role in shaping which cutting-edge ventures make it into the portfolio.
Early Deployments Already Underway
The ink on the fund may be dry only recently, but the capital is already being put to work.
Sofinnova has begun investing in several early portfolio companies and plans to continue supporting emerging biotech and medtech teams, whether they’re just getting off the ground or raising follow-on rounds.
The geographic focus remains broad, spanning both Europe and North America.
A Year of Significant Growth for the Firm
This fund close is part of a much bigger picture for Sofinnova.
Across its entire platform, the firm has gathered roughly €1.5 billion in fresh capital over the last twelve months.
With roots dating back to 1972, Sofinnova has spent more than half a century backing over 500 companies and helping build global market leaders.
Today, the firm oversees more than €4 billion in assets—solidifying its position among Europe’s most seasoned life sciences investors.
Looking Ahead
As Sofinnova Capital XI moves deeper into deployment, all eyes will be on the new ventures emerging from this sizable pool of capital.
With strong global support and decades of experience behind the wheel, the firm seems poised to shepherd the next chapter of biotech and medtech breakthroughs.
Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn